Prucalopride: Một Đánh Giá Về Việc Sử Dụng Trong Quản Lý Tình Trạng Táo Bón Mãn Tính

Tack J, Müller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation: a European perspective. Neurogastroenterol Motil. 2011;23(8):697–710. Wong BS, Manabe N, Camilleri M. Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroentrol. 2010;3:49–56. Quigley EMM. Prucalopride: safety, efficacy and potential applications. Ther Adv Gastroenterol. 2012;5(1):23–30. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91. Liu LWC. Chronic constipation: current treatment options. Can J Gastroenterol. 2011;25 Suppl B:22B–8B. European Medicines Agency. Resolor (prucalopride) film-coated tablets: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf (Accessed 8 Oct 2013). Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998;42(4):511–6. Poen AC, Felt-Bersma RJF, Van Dongen PAM, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 1999;13(11):1493–7. Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999;44(5):682–6. De Schryver AMP, Andriesse GI, Samsom M, et al. The effects of the specific 5HT4 receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther. 2002;16(3):603–12. Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects [abstract no. 745]. Gastroenterology. 2013;144(5 Suppl 1):S134. Boyce MJ, Kerstens R, Beyens G, et al. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials [abstract no. T1265]. Gastroenterology. 2009;136(5 Suppl 1):A535. Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012;73(2):203–9. Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief: results of a double-blind, placebo-controlled clinical trial. Digestion. 2003;67(1–2):82–9. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120(2):354–60. Sloots CEJ, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16(4):759–67. Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16(7):1347–56. Emmanuel AV, Kerstens R, Vandeplassche LM. Prucalopride improves bowel function and colonic transit time in patients with constipation [abstract no. Mo1326]. Gastroenterology. 2011;140(5 Suppl 1):S612. Briejer MR, Bosmans J-P, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001;423(1):71–83. De Maeyer JH, Lefebvre RA, Schuurkes JAJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20(2):99–112. Mader R, Kocher T, Haier J, et al. Investigation of serotonin type 4 receptor expression in human and non-human primate gastrointestinal samples. Eur J Gastroenterol Hepatol. 2006;18(9):945–50. Prins NH, Akkermans LM, Lefebvre RA, et al. 5-HT4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol. 2000;131(5):927–32. Prins NH, Shankley NP, Welsh NJ, et al. An improved in vitro bioassay for the study of 5-HT4 receptors in the human isolated large intestinal circular muscle. Br J Pharmacol. 2000;129(8):1601–8. Prins NH, Van Haselen JFWR, Lefebvre RA, et al. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol. 1999;127(6):1431–7. Briejer MR, Prins NH, Schuurkes JAJ. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil. 2001;13(5):465–72. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol. 2007;554(2–3):98–105. Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K+ channel. J Pharmacol Exp Ther. 2001;299(3):1007–12. European Medicines Agency. Resolor (prucalopride): EU public assessment report. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001012/WC500053997.pdf (Accessed 8 Oct 2013). Pau D, Workman AJ, Kane KA, et al. Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with β-adrenoceptor antagonists. J Pharmacol Exp Ther. 2005;313(1):146–53. Krobert KA, Brattelid T, Levy FO, et al. Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants. Naunyn Schmiedebergs Arch Pharmacol. 2005;371(6):473–9. De Maeyer JH, Schuurkes JAJ, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol. 2009;156(2):362–76. De Maeyer JH, Straetemans R, Schuurkes JAJ, et al. Porcine left atrial and sinoatrial 5-HT4 receptor-induced responses: fading of the response and influence of development. Br J Pharmacol. 2006;147(2):140–57. Van de Velde VJ, Ausma J, Vandeplassche L. I.V. kinetics and absolute oral bioavailability of prucalopride [abstract no. S1331]. Gastroenterology. 2010;138(5 Suppl 1):S230. Van de Velde VJ, Ausma J, Vandeplassche L. Food does not affect the oral bioavailability of prucalopride [abstract no. T1270]. Gastroenterology. 2009;136(5 Suppl 1):A536. Van de Velde VJ, Ausma J, Vandeplassche L. Comparative pharmacokinetics of prucalopride in healthy young and elderly subjects [abstract no. S1330]. Gastroenterology. 2010;138(5 Suppl 1):S230. Chen X, Jiang J, Liu T, et al. Pharmacokinetics of single and repeated oral doses of prucalopride in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2012;50(11):797–804. Janssen-Cilag Pty Ltd. Resotrans™ (prucalopride) tablets: Australian prescribing information. 2011. https://www.ebs.tga.gov.au (Accessed 8 Oct 2013). Janssen Inc. Resotran™ (prucalopride) tablets: Canadian prescribing information. 2012. http://www.hc-sc.gc.ca (Accessed 8 Oct 2013). Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr. 2013;57(2):197–203. Smith WB, Mannaert E, Verhaeghe T, et al. Effect of renal impairment on the pharmacokinetics of prucalopride: a single-dose open-label phase I study. Drug Des Dev Ther. 2012;6:407–15. Van de Velde V, Vandeplassche L, Hoppenbrouwers M, et al. Effect of prucalopride on the pharmacokinetics of oral contraceptives in healthy women. Drugs R D. 2013;13(1):43–51. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344–54. Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29(3):315–28. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357–65. Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 2012;24(11):999-e541. Müller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22(9):991–8, e255. Gatta L, Kerstens R, Scarpignato C. How effective is prucalopride for the treatment of chronic constipation? A systematic review and meta-analysis [abstract no. Su2069]. Gastroenterology. 2013;144(5 Suppl 1):S547–8. Cheng E. Efficacy of prucalopride in the treatment of chronic constipation: a systematic review and meta-analysis of randomized controlled trials [abstract]. Clin Gastroenterol Hepatol. 2012;10(3):329–30. Tack J, Quigley E, Camilleri M, et al. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United Eur Gastroenterol J. 2013;1:48–59. Tack J, Stanghellini V, Dubois D, et al. Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil. 2013;. doi:10.1111/nmo.12217. Ke MY, Zou DW, Yuan YZ, et al. Treatment with prucalopride for chronic constipation improves the symptoms and quality of life of patients in China [abstract no. PGI16]. Value Health. 2012;15(7):A637-8 plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research 5th Asia-Pacific Conference; 2–4 Sep 2012; Taipei. Stanghellini V, Vandeplassche L, Kerstens R. Best response distribution of 12-week treatment with prucalopride (Resolor) in patients with chronic constipation: combined results of three randomised, double-blind, placebo-controlled phase III trials [abstract no. PWE-075]. Gut. 2011;60 Suppl 1:A159–60. Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation—follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010;32(9):1113–23. Cinca R, Chera D, Gruss H-J, et al. Randomised clinical trial: macrogol/PEG 3350 + electrolytes versus prucalopride in the treatment of chronic constipation: a comparison in a controlled environment. Aliment Pharmacol Ther. 2013;37(9):876–86. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21(12):1256–63, e117. Movetis. Movetis receives authorisation to market Resolor® in Switzerland [media release]; 2010. http://www.movetis.com (Accessed 8 Oct 2013). Lacy BE, Levenick JM, Crowell M. Chronic constipation: new diagnostic and treatment approaches. Ther Adv Gastroenterol. 2012;5(4):233–47. Lindberg G, Hamid SS, Malfertheiner P, et al. World Gastroenterology Organisation global guideline: constipation—a global perspective. J Clin Gastroenterol. 2011;45(6):483–7. Bove A, Bellini M, Battaglia E, et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol. 2012;18(36):4994–5013. Portalatin M, Winstead N. Medical management of constipation. Clin Colon Rectal Surg. 2012;25(1):12–9. Herring C. Prucalopride. Clin Pharmacist. 2011;3(2):55–7. Shire Development LLC. Evaluation of prucalopride in male subjects with chronic constipation [ClinicalTrials.gov identifier NCT01147926]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www.clinicaltrials.gov/ct2/show/NCT01147926 (Accessed 8 Oct 2013). Shire-Movetis NV. Study to investigate prucalopride vs. polyethylene glycol 3350 on colon activity [ClinicalTrials.gov identifier NCT01707667]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www.clinicaltrials.gov/ct2/show/NCT01707667 (Accessed 8 Oct 2013). Stanghellini V, Vandeplassche LM, Kerstens R, et al. The relation between adverse events on day 1 and pharmacodynamic effects on day 1 of treatment with prucalopride [abstract no. Mo1336]. Gastroenterology. 2011;140(5 Suppl 1):S615. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745–67. Sanger GJ, Quigley EMM. Constipation, IBS and the 5-HT4 receptor: what role for prucalopride? Clin Med Insights Gastroenterol. 2010;3:21–33. Tack J, Corsetti M. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert Opin Drug Metab Toxicol. 2012;8(10):1327–35. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58(1):32–45. Sloots CEJ, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10):2912–21. Movetis. Prucalopride effects on subjects with chronic non-cancer pain suffering from opioid induced constipation (OIC) [ClinicalTrials.gov identifier NCT01117051]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www.clinicaltrials.gov/ct2/show/results/NCT01117051 (Accessed 8 Oct 2013). Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction—a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012;35(1):48–55.